• S Tag Peptide (SKU A6007): Technical Guidance for Lab Use

  2026-04-23

  S Tag Peptide is designed to enhance recombinant protein solubility and enable straightforward detection and purification workflows. It is best applied to molecular biology and protein engineering contexts where improving expression quality and supporting anti-S-Tag antibody-based assays is critical. Its use is not suitable for applications requiring ethanol solubility or long-term solution storage.

• Cisapride (R 51619): Redefining Predictive Cardiotoxicity Sc

  2026-04-22

  This thought-leadership article explores how Cisapride (R 51619) empowers next-generation predictive cardiotoxicity platforms by bridging mechanistic insight, phenotypic validation, and translational impact. Anchored in recent advances, including deep learning-enabled iPSC-cardiomyocyte assays, we synthesize strategic guidance for researchers seeking to de-risk early-stage drug development and set new standards in cardiac electrophysiology research.

• Bedaquiline (SKU B3492): Reliable Solutions for TB & Cancer

  2026-04-22

  This article provides a scenario-driven analysis of Bedaquiline (SKU B3492), emphasizing its validated role in cell viability, cytotoxicity, and proliferation assays for both tuberculosis and cancer metabolism research. Drawing on peer-reviewed data and practical workflow recommendations, it guides biomedical scientists toward reproducible, efficient experimental setups with actionable protocol parameters.

• Sunitinib: Multi-Targeted RTK Inhibitor for Advanced Cancer

  2026-04-21

  Sunitinib empowers researchers with robust, multi-pathway inhibition for dissecting angiogenesis, proliferation, and apoptosis in cancer models. Discover protocol refinements, troubleshooting insights, and evidence-driven strategies to maximize translational impact in renal cell carcinoma, nasopharyngeal carcinoma, and ATRX-deficient glioma research.

• Insulin-AMPK Regulation of Pink1 mRNA Localization in Neuron

  2026-04-21

  This study uncovers how insulin signaling modulates the localization of Pink1 mRNA in neurons via AMPK activity, thereby controlling PINK1 protein function and mitochondrial quality control. The findings establish a mechanistic link between metabolic cues, insulin resistance, and neuronal mitophagy, offering new insights for neurodegeneration research.

• Ridaforolimus (Deforolimus, MK-8669): Reliable mTOR Inhibiti

  2026-04-20

  This article addresses practical laboratory challenges in cell viability, proliferation, and angiogenesis assays, illustrating how Ridaforolimus (Deforolimus, MK-8669) (SKU B1639) delivers reproducible and sensitive results. Drawing on published data and validated protocols, it provides actionable guidance for biomedical researchers seeking high-quality, cost-effective mTOR inhibition in cancer and senescence studies.

• DAPI (hydrochloride): Workflow Guide for DNA Visualization

  2026-04-20

  DAPI (hydrochloride) offers precise DNA visualization for chromosome staining, cell cycle analysis, and histochemistry workflows. It excels in fixed cell and chromosome applications, but requires careful optimization when used with live cells due to low permeability. Not recommended for ethanol-based protocols or applications needing high live-cell permeability.

• Nilotinib (AMN-107): Transforming Translational Oncology Res

  2026-04-19

  This thought-leadership article explores the mechanistic and strategic frontiers of Nilotinib (AMN-107) in translational cancer research. We examine its selective targeting of BCR-ABL and KIT mutants, new evidence for immunomodulatory effects, and actionable guidance for experimental design—bridging molecular insight with workflow innovation. The piece contextualizes emerging data, including Dong et al.'s groundbreaking findings on MHC-I restoration in colorectal cancer, positioning Nilotinib as a catalyst for both deep mechanistic studies and the next wave of combination immunotherapies.

• CAF-Derived Lactate Drives Oxaliplatin Resistance via ANTXR1

  2026-04-18

  This study uncovers a mechanistic link between cancer-associated fibroblast (CAF)-derived lactate and oxaliplatin resistance in colorectal cancer, mediated by ANTXR1 lactylation and enhanced cancer stemness. The findings suggest that targeting the lactate shuttle or stromal-tumor interactions could improve chemotherapy outcomes.

• Eltanexor (KPT-8602): Optimizing XPO1 Inhibition in Cancer A

  2026-04-17

  Eltanexor (KPT-8602) delivers robust, reproducible inhibition of XPO1, empowering cancer researchers to dissect nuclear export pathways with precision. See how optimized protocols and troubleshooting insights can maximize assay reliability and translational impact.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-04-16

  This study systematically characterizes the prevalence and transmission of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China. The findings reveal high rates of multidrug resistance and successful gene transfer, with major implications for research on Gram-negative bacterial infection and antimicrobial stewardship.

• Protease Inhibitor Cocktail (MS-SAFE, 50X): MS-Compatible Us

  2026-04-15

  Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) is designed to prevent protein degradation during extraction, particularly in workflows requiring mass spectrometry compatibility. It is not suitable for workflows where metalloproteinase inhibition is necessary unless EDTA is added separately, and its use should be avoided in non-aqueous or incompatible solvent systems.

• Biotin-XX Tyramide Reagent: Advanced Cell Surface Labeling

  2026-04-14

  Biotin-XX Tyramide Reagent delivers unmatched sensitivity and selectivity for cell surface protein labeling, driving next-generation proximity labeling and tyramide signal amplification in neuroscience and cell biology. Its membrane-impermeant design uniquely empowers high-resolution mapping of extracellular proteomes, overcoming challenges in low-abundance target detection and neurotransmitter interference.

• Lymphodepleting Chemotherapy Enhances Neoantigen T Cell Ther

  2026-04-13

  Sagie et al. demonstrate that lymphodepleting chemotherapy augments the efficacy of neoantigen-directed adoptive T cell therapy by remodeling tumor antigen presentation. Through upregulation of immunoproteasome activity and HLA class I expression, chemotherapy synergizes with engineered TCR-T cells to improve tumor recognition and killing, offering a mechanistic rationale for combined regimens in solid tumor immunotherapy.

• Dual-Action p38α MAPK Inhibitors: Mechanistic Insights and A

  2026-04-13

  The referenced study uncovers how certain p38α MAPK inhibitors not only block kinase activity but also accelerate activation loop dephosphorylation by phosphatases, revealing a dual-action mechanism. These findings suggest new strategies for enhancing specificity and potency in kinase inhibitor research, with implications for inflammation and disease models.

8625 records 15/575 page Previous Next First page 上5页 1112131415 下5页 Last page